NOVARTIS AG
No SEC Form 4 filings for $NVS in the last 30 days.
See all $NVS insider activity →Novartis (NVS) stock rose 3.2% today, likely due to investor optimism around remibrutinib, which received FDA approval for symptomatic dermographism and showed positive Phase III data in relapsing multiple sclerosis. The company plans an investor call on October 23, 2026, to discuss the MS program.
Swiss stocks rose 1.45% on Wednesday, extending gains to a fourth session. The SMI closed at 14,129.93. Lonza, Roche, Sandoz, Novartis, and Galderma gained 2.7%-3.35%.
Novartis AG sold Indian trademark rights to USV, Cipla, and Eris Lifesciences for Rs 433.14 crore. The Indian tax authority initially treated the sale as taxable royalty, but the Tribunal ruled it was not taxable in India under the India-Switzerland DTAA, as the consideration was for alienation of rights, not royalties.
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning NVS (NOVARTIS AG). Coverage has skewed bullish: 11 bullish, 2 neutral, and 2 bearish.
Recent NVS coverage spans financial news, regulation and market movers.
The approval expands the drug's market and supports further growth, likely sustaining price gains.
Positive price move on market momentum.
Potential reduction in tax expense for Novartis.
The ruling secures Novartis's market exclusivity for Entresto, likely supporting its pricing power.
Regulatory approval should reduce US access friction for Lamprene and can support renewed US commercialization prospects.
AlphAI scores every news story that mentions NVS with an AI model for sentiment and relevance, and aggregates insider trades from NOVARTIS AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Novartis (NVS) stock rose 3.2% today, likely due to investor optimism around remibrutinib, which received FDA approval for symptomatic dermographism and showed positive Phase III data in relapsing multiple sclerosis. The company plans an investor call on October 23, 2026, to discuss the MS program.
2 min readSwiss stocks rose 1.45% on Wednesday, extending gains to a fourth session. The SMI closed at 14,129.93. Lonza, Roche, Sandoz, Novartis, and Galderma gained 2.7%-3.35%.
1 min readNovartis AG sold Indian trademark rights to USV, Cipla, and Eris Lifesciences for Rs 433.14 crore. The Indian tax authority initially treated the sale as taxable royalty, but the Tribunal ruled it was not taxable in India under the India-Switzerland DTAA, as the consideration was for alienation of rights, not royalties.
1 min readThe UK High Court ruled in favor of Novartis, upholding its SPC for the combination of sacubitril and valsartan in Entresto®. The court defined the protected 'product' as the combination of these active ingredients, not the specific co-crystal formulation. This decision impacts Novartis's patent protection and potential competition from generic versions.
2 min readNovartis' Lamprene (clofazimine) for leprosy treatment received FDA approval on July 27, 2024, after the company stopped marketing it in the US. The approval was announced to healthcare professionals on Oct. 9, 2024.
2 min readBofA believes Novartis will need $13B in additional revenue by 2033 to offset patent expirations. The bank expects the company to achieve this through higher sales of existing products and new pipeline candidates. Novartis' 2027 P/E ratio reflects confidence in its post-2031 growth strategy, according to BofA.
2 min readBank of America anticipates Novartis will exceed consensus expectations for midterm guidance during its upcoming Capital Markets Day. The company's stock has seen a 5-day increase of 0.56%, a 1st Jan change of 2.70%, and a 9.14% year-to-date gain.
1 min readNovartis has agreed to a $7.8 billion deal with Chinese company Abogen to develop mRNA technology. The US is reportedly considering allowing such pharmaceutical partnerships with China to continue, despite a more cautious approach in other sectors. According to the report, this deal highlights ongoing collaboration in the pharmaceutical industry between the US and China.
1 min readNovartis, Thermo Fisher, Takeda, Rockwell Automation, and others launched the Digital CMC Consortium to modernize drug development. The group aims to replace manual processes with digital standards, AI, and interoperable infrastructure. Novartis and Rockwell Automation highlighted cost-sharing and efficiency benefits. The consortium's initial focus is improving technology transfer in pharmaceutical manufacturing.
4 min readNovartis AG (NOVN) invested $575M in Abogen for ABO2203 mRNA T-cell engagers, with up to $7.8B in milestones. Novartis gained FDA approval for Rhapsido (remibrutinib) for dermographism, showing 29.3% complete hive clearance. The company will present late-breaking Kesimpta MS data and hold an investor call on REMODEL data.
1 min read
